medigraphic.com
ISSN 1560-4381 (Print)

2013, Number 3

<< Back Next >>

Correo Científico Médico 2013; 17 (3)

Chronic Hepatitis in Donors and Non-Blood Donors with Positive Antibodies to the Virus C

Mulet PA, Gámez EM, Ferrer LR, Pullés LM, Rubio RA, García CM

Language: Spanish
References: 30
Page: 1-17
PDF size: 312.66 Kb.


ABSTRACT

Introduction: the hepatitis C virus infection, problem of worldwide health is one of the main causes of chronic hepatitis and liver cirrhosis.
Objective: to identify whether there are differences or not in the frequency of occurrence of chronic hepatitis and their clinical characteristics, humoral and pathological, between donors and non-blood donors with antibodies to HCV (anti-HCV) positive.
Methods: the study group comprised all patients with anti-HCV positive, diagnosed by ultramicroelisa in Provincial Blood Bank, treated from January 2000 to December 2011, in General University Hospital Vladimir Ilich Lenin of Holguin. Liver biopsy was performed to patients. Two intentional samples were selected: patients diagnosed with chronic hepatitis study group and control group 46 donors, 17 non-blood donors without virus surface antigen pretreatment B or interferon and ribavirin.
Results: chronic hepatitis was higher (P ‹0.05) in the control group, with more active forms with or without severe fibrosis (P ‹0.001), and alaninoaminotransferasas (ALAT) altered (p ‹0.001), unlike the study group prevalence of hepatitis with mild activity or minimal and normal ALAT. Donors were minority symptomatic difference (p ‹0.001) than non-donors, 82% with symptoms, in decreasing order: asthenia (14), right upper quadrant discomfort (12) and dyspepsia (7).
Conclusions: the lower frequency of chronic hepatitis with positive HCV in blood donors, predominantly minimal to slight activity, could be due to early diagnosis in early stages of the disease. Asymptomatic donors with normal transaminases predominated on non-donors, which could correspond to the magnitude of the activity and stage of chronic hepatitis those ones.


REFERENCES

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatol. 2013[citado 13 dic 2012]; 57(4):1333-42Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23172780

  2. Modi A, Liang TJ. Hepatitis C: a clinical review. Oral Disease. 2008; 14(1):10-14.

  3. Christoph. B, Wasmuth JC. Hepatitis C- Epidemiology transmission and natural history in Hepatology. Washington: Flying Publisher; 2010.

  4. Sheik M, Atla P, Ameer A, Sadiq H, Sadler P. Seroprevalence of Hepatitis B and C infection among healthy volunteer blood donors in the Center California Valley. Gut and Liver. 2013; 7(1): 66-73.

  5. Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J,et al. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis. 2012; 206(5):654-61.

  6. Chimparlee N, Oota S, Phikulsod S, Tangkijvanich P, Poovorawan Y. Hepatitis B and hepatitis C virus in Thai blood donors. Southeast Asian J Trop Med Public Health. 2011; 42(3):609-15.

  7. Baha W, Foullous A, Dersi N, They-They TP, Alaoui K, Nourichafi N, et al Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health. 2013;13(1):50.

  8. Jiménez Ceballos L. Alteraciones hepáticas en donantes de sangre asintomáticos con anticuerpo al virus de la Hepatitis C positivo. (Tesis) Holguín: Hospital General Universitario Vladimir Ilich Lenin; 1997.

  9. Mulet Pérez A, Arencibia Vidal É, Gámez Escalona M, Pullés Labadié M, Pérez Lorenzo M, Mulet Gámez A. Alteraciones clínicas, humorales, laparoscópicas e hísticas hepáticas en donantes de sangre con anticuerpo al VHC positivo. Rev Cubana Med Mil. 2009 [citado: 6 mar 2013]; 38(1). Disponible en: http://bvs.sld.cu/revistas/mil/vol38_1_09/mil05109.htm

  10. Dienstag Jl, Isselbacher KJ. Hepatitis Crónica. En: Braunwald E, Fauci Kasper D, Hauser S, Longo D, Jameson JL. Harrison. Manual de Medicina. 15 ed. Madrid: Mc Graw Hill; 2002. p. 716-9.

  11. Arús E. Historia natural de la infección por el virus de la hepatitis C en Hepatología 2006. La Habana: Editorial CIMEQ;2006:15-28.

  12. Serfaty L, Nousbaum JB, Elghouzzi MH, Legendre C, Poupon R. Prevalence, severity and factors of liver in blood donors. Hepatol. 2005; 21(3):725-9.

  13. Ríos M, Diago M, Rivera P, Tuset C, Cors R, García V, et al. Epidemiological, biological and histological characterization of patients with indeterminate third-generation recombinant immunoblot assay antibody results for hepatitis C virus. J Viral Hepat. 2006; 13(3):177-81.

  14. Castellanos G, Carreras Pérez M. Esteatosis y esteatohepatitis no alcohólica. En: Berenguer Lapuerta J, Bruguera Bengochea M, García Bengochea M. Tratamiento de las enfermedades hepáticas y biliareseditores. 2da ed. Madrid: Asociación Española de Enfermedades Hepáticas y Biliares; 2006.p.2011-2012.

  15. Bosques Padillas F. Infección por el virus de la Hepatitis C y Esteatosis hepática. Gac Méd Mexico. 2004; 140(Supl.2):73-76.

  16. Mulet Pérez A. Hígado graso. Holguín: Editorial Oriente; 2008.

  17. Richter S. Laboratory Assays for diagnosis and management of hepatitis C virus infection. J Clin Microbiol. 2002; 40:4407-4412.

  18. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012; 55 (Suppl 1): 43- 48.

  19. Kuo YH, Chang KCh, Wang JH, Tsai PS, Hung SF, Hung CH, et al. Is Hepatitis C Virus Core Antigen an adequate marker for community screening? J Clin Microbiol.2012; 50(6):1989-93.

  20. Mauss S. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepatitis.2011; 18: 81-90.

  21. Backus LI, Boothroyd DB, Philps BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatol. 2007; 46:37-47.

  22. Serra Delfis MA. Tratamiento de las hepatitis crónicas víricas en situaciones especiales en Tratamiento de las enfermedades hepáticas y biliares. 2da ed. Madrid: Asociación Española de Enfermedades Hepáticas y Biliares; 2006.

  23. Infante M, Arús E, Fernández N. Hallazgos clínicos, bioquímicos y morfológicos en 103 pacientes con anticuerpos contra la Hepatitis C. Rev Cubana Med.1998 [citado 24 abr 2012]; 37(2):66-71. Disponible en: http://bvs.sld.cu/revistas/med/vol37_2_98/med02298.htm

  24. Rodríguez Torres M. Latinos and Chronic hepatitis C: a singular population. Clinical Gastroenterol Hepatol. 2008 [citado 24 abr 2012]; 5:484-490. Disponible en: http://www.cghjournal.org/article/S1542-3565%2808%2900198-5

  25. Liu T, Xiaoming Wang X, Morten A, Karsdal MA, Diana J, Leeming DJ, et al. Molecular serum markers of liver fibrosis Biomark Insights. J Clin Microbiol.2012; 7: 105–17.

  26. Scottish Intercollegiate Guidelines Network. Management of hepatitis C. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2006.

  27. Arús Soler E. Clínica y terapéutica de las hepatitis virales. En: Padrón González G. Bases moleculares para el estudio de las hepatitis virales. La Habana: Editorial Elfos Scientiae; 1998.p.43-78.

  28. Llanio Navarro R, Perdomo González G, Arús Soler E, Fernández Naranjo A, Fernández Sacasa J, Matarama Peñate M, et al. Propedéutica clínica y semiología médica. La Habana: Editorial Ciencias Médicas; 2005.

  29. Lange C, Sarrazin C. Diagnostic test in acute and chronic hepatitis C. Washington: Flying Publisher; 2012.

  30. Sánchez Tapia JM. Hepatitis crónica por el virus de la hepatitis C. En: Asociación Española para el Estudio del Hígado. Tratamiento de las enfermedades hepáticas y biliares. 2da ed. Madrid: Asociación Española para el Estudio del Hígado; 2001.p. 41-53.




2020     |     www.medigraphic.com